Published in Vaccine on November 06, 2009
Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol (2012) 2.65
Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol (2010) 1.83
Immunology of gut mucosal vaccines. Immunol Rev (2011) 1.59
Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol (2011) 1.51
Vaccinating against Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol (2011) 1.14
A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect Immun (2013) 0.98
Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae. Mucosal Immunol (2011) 0.98
Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes. J Immunol (2014) 0.97
Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli. Clin Vaccine Immunol (2013) 0.97
The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infect Immun (2012) 0.93
Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. Vaccine (2013) 0.89
The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens. PLoS One (2012) 0.88
Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity. PLoS One (2013) 0.84
Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide. PLoS Negl Trop Dis (2014) 0.80
Vaccine approaches for multidrug resistant Gram negative infections. Curr Opin Immunol (2014) 0.80
Simultaneous exposure to Escherichia coli heat-labile and heat-stable enterotoxins increases fluid secretion and alters cyclic nucleotide and cytokine production by intestinal epithelial cells. Infect Immun (2014) 0.79
Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. Hum Vaccin Immunother (2014) 0.78
Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection. Clin Vaccine Immunol (2015) 0.77
A live attenuated Salmonella Enteritidis secreting detoxified heat labile toxin enhances mucosal immunity and confers protection against wild-type challenge in chickens. Vet Res (2016) 0.75
Induction of mucosal immune responses against Helicobacter pylori infection after sublingual and intragastric route of immunization. Immunology (2016) 0.75
Adjuvant-Mediated Epitope Specificity and Enhanced Neutralizing Activity of Antibodies Targeting Dengue Virus Envelope Protein. Front Immunol (2017) 0.75
Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med (1991) 23.89
Test for enterotoxigenic Escherichia coli using Y-1 adrenal cells in miniculture. Infect Immun (1975) 13.58
Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med (1991) 11.98
Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ (1991) 9.88
Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet (1990) 9.49
A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology (1997) 7.72
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med (1992) 6.64
Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect Immun (1991) 5.90
Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science (1995) 5.73
Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology (1991) 4.86
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun (1995) 3.22
Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology (1998) 2.79
Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology (1999) 2.72
Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med (1998) 2.70
Helicobacter pylori and gastric carcinoma. Serum antibody prevalence in populations with contrasting cancer risks. Cancer (1990) 2.32
The transmission of Helicobacter pylori. A critical review of the evidence. Int J Epidemiol (1995) 2.10
A comprehensive review of the natural history of Helicobacter pylori infection in children. Arch Med Res (2001) 1.85
Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine (1998) 1.58
Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun (1997) 1.57
Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immun (1998) 1.54
Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine. Infect Immun (1994) 1.51
Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun (2001) 1.50
Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun (2000) 1.44
Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine (1999) 1.41
Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology (2008) 1.26
Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine (1995) 1.25
Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice. Infect Immun (1995) 1.24
Review article: Pathogenesis of the transformation from gastritis to malignancy. Aliment Pharmacol Ther (1998) 1.23
Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut (2006) 1.20
Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines. Infect Immun (2002) 1.12
Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine (2001) 1.09
Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection. Lancet (1996) 1.03
Vaccines against Campylobacter jejuni. J Infect Dis (1997) 1.03
The microbiology and epidemiology of Helicobacter pylori infection. Scand J Gastroenterol Suppl (1994) 1.02
Comparison between targeted and untargeted systemic immunizations with adjuvanted urease to cure Helicobacter pylori infection in mice. Vaccine (1999) 0.95
The association of Helicobacter pylori with gastric cancer and preneoplastic gastric lesions in Chiapas, Mexico. Cancer (1993) 0.94
Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine (2002) 0.90
Progress in vaccine development against Helicobacter pylori. FEMS Immunol Med Microbiol (2007) 0.90
B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H pylori seronegative individuals. Vaccine (2003) 0.86
Vaccination against Helicobacter pylori in non-human primate models and humans. Scand J Immunol (2001) 0.83
Immunisation against Helicobacter felis infection protects against the development of gastric MALT Lymphoma. Vaccine (2004) 0.81
Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. Aliment Pharmacol Ther (1999) 0.78
Helicobacter animal models. Curr Protoc Immunol (2001) 0.77
The 'permeome' of the malaria parasite: an overview of the membrane transport proteins of Plasmodium falciparum. Genome Biol (2005) 1.91
The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res (2005) 1.60
Presynaptic Ca2+ channels: a functional patchwork. Trends Neurosci (2003) 1.57
Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood (2005) 1.54
Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol (2011) 1.51
Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect Immun (2011) 1.41
CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G). J Virol (2002) 1.32
Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis (2003) 1.32
Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens. Vaccine (2005) 1.27
Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol (2010) 1.25
Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol (2009) 1.20
Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis. Clin Vaccine Immunol (2013) 1.17
Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging (2002) 1.15
Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect Immun (2005) 1.14
Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol (2011) 1.10
Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol (2003) 1.09
Presynaptic and postsynaptic mechanisms underlie paired pulse depression at single GABAergic boutons in rat collicular cultures. J Physiol (2002) 1.08
Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine (2011) 1.07
Binding site stoichiometry and the effects of phosphorylation on human alpha1 homomeric glycine receptors. J Physiol (2002) 1.06
Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. Infect Immun (2010) 1.05
Intranasal administration of an Escherichia coli-expressed codon-optimized rotavirus VP6 protein induces protection in mice. Protein Expr Purif (2004) 1.03
Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine. Infect Immun (2013) 1.02
Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen. Vaccine (2012) 0.98
Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother (2013) 0.98
Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera. Clin Vaccine Immunol (2012) 0.98
Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses. Vaccine (2002) 0.98
Development of a Bacillus subtilis-based rotavirus vaccine. Clin Vaccine Immunol (2010) 0.98
Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens. Vaccine (2007) 0.97
Comparison of taurine- and glycine-induced conformational changes in the M2-M3 domain of the glycine receptor. J Biol Chem (2004) 0.97
IFN-gamma is the only anti-rotavirus cytokine found after in vitro stimulation of memory CD4+ T cells from mice immunized with a chimeric VP6 protein. Viral Immunol (2007) 0.97
Role of B7 costimulatory molecules in the adjuvant activity of the heat-labile enterotoxin of Escherichia coli. J Immunol (2002) 0.96
Effectiveness of the quillaja saponin semi-synthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis. Vaccine (2003) 0.95
Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J Virol (2010) 0.95
Pathology and pathophysiology of inhalational anthrax in a guinea pig model. Infect Immun (2013) 0.93
The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infect Immun (2012) 0.93
The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine (2002) 0.92
Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting". Vaccine (2003) 0.91
Functional mapping of protective epitopes within the rotavirus VP6 protein in mice belonging to different haplotypes. Vaccine (2003) 0.90
Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. Vaccine (2013) 0.89
Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA. Virology (2006) 0.89
Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes. Infect Immun (2009) 0.89
The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens. PLoS One (2012) 0.88
Recombinant human uteroglobin/CC10 inhibits the adhesion and migration of primary human endothelial cells via specific and saturable binding to fibronectin. J Cell Physiol (2006) 0.88
Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109. Vaccine (2006) 0.87
Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV. Vaccine (2006) 0.87
Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge. Vaccine (2007) 0.87
Evaluation of combinatorial vaccines against anthrax and plague in a murine model. Vaccine (2007) 0.86
Adenosine triphosphate acts as both a competitive antagonist and a positive allosteric modulator at recombinant N-methyl-D-aspartate receptors. Mol Pharmacol (2004) 0.86
Hydration effects on skin microstructure as probed by high-resolution cryo-scanning electron microscopy and mechanistic implications to enhanced transcutaneous delivery of biomacromolecules. J Pharm Sci (2010) 0.85
Identification of an immunodominant CD4+ T cell epitope in the VP6 protein of rotavirus following intranasal immunization of BALB/c mice. Virology (2007) 0.84
Characterization of heat-stable (STa) toxoids of enterotoxigenic Escherichia coli fused to double mutant heat-labile toxin peptide in inducing neutralizing Anti-STa antibodies. Infect Immun (2014) 0.84
Effectiveness of the B subunit of cholera toxin in potentiating immune responses to the recombinant hemagglutinin/adhesin domain of the gingipain Kgp from Porphyromonas gingivalis. Vaccine (2005) 0.83
Induction of increased permeability of polarized enterocyte monolayers by enterotoxigenic Escherichia coli heat-labile enterotoxin. Am J Trop Med Hyg (2011) 0.83
Cholera-like enterotoxins and Regulatory T cells. Toxins (Basel) (2010) 0.82
Dynamics of forward and reverse transport by the glial glycine transporter, glyt1b. Biophys J (2005) 0.82
Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free injection. Vaccine (2007) 0.82
Effect of anthrax immune globulin on response to BioThrax (anthrax vaccine adsorbed) in New Zealand white rabbits. Antimicrob Agents Chemother (2013) 0.81
Dose response to rhCC10-augmented surfactant therapy in a lamb model of infant respiratory distress syndrome: physiological, inflammatory, and kinetic profiles. J Appl Physiol (1985) (2005) 0.80
Production of a recombinant antibody fragment in whole insect larvae. Mol Biotechnol (2007) 0.79
Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity. Br J Clin Pharmacol (2011) 0.79
Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. Hum Vaccin Immunother (2014) 0.78
Automated threshold detection for auditory brainstem responses: comparison with visual estimation in a stem cell transplantation study. BMC Neurosci (2009) 0.78
Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV(89.6). Virology (2003) 0.77
Induction of serum and mucosal FIV-specific immune responses by intranasal immunization with p24Gag. Vaccine (2005) 0.76
Unexpected modulation of recall B and T cell responses after immunization with rotavirus-like particles in the presence of LT-R192G. Toxins (Basel) (2010) 0.76
Mesenchymal stem cells as a novel vaccine platform. Front Cell Infect Microbiol (2012) 0.76